Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  73 results for ""MAP Kinase Kinase 1""

Your Filters

Subject : antineoplastic combined chemotherapy protocols
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells.

  • Authors : Kan G; State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Sun Yat-sen University Cancer Center Guangzhou Guangdong 510060 P. R. China.; Wang Z

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*pharmacology ; Cell Cycle Proteins/Cell Cycle Proteins/Cell Cycle Proteins/*antagonists & inhibitors ; Colorectal Neoplasms/Colorectal Neoplasms/Colorectal Neoplasms/*drug therapy

  • Source: Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2021 Mar 15; Vol. 8 (10), pp. 2004344. Date of Electronic Publication: 2021 Mar 15 (Print Publication: Publisher: WILEY-VCH Country of Publication: Germany NLM ID: 101664569 Publication Model: eCollection Cited Medium: Internet ISSN: 2198-3844

Record details

Read More Add to Saved list
×
Academic Journal

MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells.

  • Authors : Jing C; Clinical Cancer Research Center, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China.; Li H

Subjects: Gene Expression Regulation, Neoplastic*; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*pharmacology ; Butadienes/Butadienes/Butadienes/*pharmacology

  • Source: Molecular medicine reports [Mol Med Rep] 2019 Feb; Vol. 19 (2), pp. 1092-1100. Date of Electronic Publication: 2018 Dec 07.Publisher: D. A. Spandidos Country of Publication: Greece NLM ID: 101475259 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case.

  • Authors : Lehtomaki KI; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland .; Tays Cancer Center, Tampere University Hospital, Tampere, Finland.

Subjects: Mutation*; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Colorectal Neoplasms/Colorectal Neoplasms/Colorectal Neoplasms/*pathology

  • Source: Anticancer research [Anticancer Res] 2019 Nov; Vol. 39 (11), pp. 5867-5877.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.

  • Authors : Tang X; Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China.

Subjects: Antineoplastic Combined Chemotherapy Protocols*; Histiocytosis, Langerhans-Cell/Histiocytosis, Langerhans-Cell/Histiocytosis, Langerhans-Cell/*drug therapy ; Histiocytosis, Langerhans-Cell/Histiocytosis, Langerhans-Cell/Histiocytosis, Langerhans-Cell/*genetics

  • Source: Annals of medicine [Ann Med] 2021 Dec; Vol. 53 (1), pp. 1537-1546.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print Cited Medium: Internet ISSN: 1365-2060

Record details

Read More Add to Saved list
×
Academic Journal

Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.

  • Authors : Nassar KW; Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*pharmacology ; Breast Neoplasms/Breast Neoplasms/Breast Neoplasms/*drug therapy ; Cyclin-Dependent Kinase 4/Cyclin-Dependent Kinase 4/Cyclin-Dependent Kinase 4/*antagonists & inhibitors

  • Source: Molecular cancer therapeutics [Mol Cancer Ther] 2021 Oct; Vol. 20 (10), pp. 2049-2060. Date of Electronic Publication: 2021 Aug 10.Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.

  • Authors : Chuang J; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA.; Wang C

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*pharmacology ; Colorectal Neoplasms/Colorectal Neoplasms/Colorectal Neoplasms/*drug therapy ; Drug Resistance, Neoplasm/Drug Resistance, Neoplasm/Drug Resistance, Neoplasm/*genetics

  • Source: Clinical colorectal cancer [Clin Colorectal Cancer] 2021 Mar; Vol. 20 (1), pp. 72-78. Date of Electronic Publication: 2020 Dec 17.Publisher: Elsevier Country of Publication: United States NLM ID: 101120693 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Report

Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition.

  • Authors : Tsakonas G; Thoracic Oncology Center, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden. Electronic address: .

Subjects: Mutation*; Adenocarcinoma of Lung/Adenocarcinoma of Lung/Adenocarcinoma of Lung/*therapy ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use

  • Source: Clinical lung cancer [Clin Lung Cancer] 2020 Nov; Vol. 21 (6), pp. e544-e546. Date of Electronic Publication: 2020 May 12.Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

BRAF -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.

  • Authors : Middleton G; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom. .; Yang Y

Subjects: Mutation*; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Colorectal Neoplasms/Colorectal Neoplasms/Colorectal Neoplasms/*drug therapy

  • Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Jun 01; Vol. 26 (11), pp. 2466-2476. Date of Electronic Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

The limitations of targeting MEK signalling in Glioblastoma therapy.

  • Authors : Selvasaravanan KD; Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.; Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany.

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*pharmacology ; Brain Neoplasms/Brain Neoplasms/Brain Neoplasms/*therapy ; Glioblastoma/Glioblastoma/Glioblastoma/*therapy

  • Source: Scientific reports [Sci Rep] 2020 May 04; Vol. 10 (1), pp. 7401. Date of Electronic Publication: 2020 May 04.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.

  • Authors : Tolcher AW; South Texas Accelerated Research Therapeutics, San Antonio, TX, USA. .; NEXT Oncology, San Antonio, USA. .

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; MAP Kinase Kinase 1/MAP Kinase Kinase 1/MAP Kinase Kinase 1/*antagonists & inhibitors

  • Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 Apr; Vol. 85 (4), pp. 673-683. Date of Electronic Publication: 2020 Feb 15.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  73 results for ""MAP Kinase Kinase 1""